KK

Kaushal Kant Verma

Active Director Director DIN 09608717
DIN 09608717 First appointment May 2022 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2022
Shareholding value •••• Premium profile

About Kaushal Kant Verma

Data last updated:

Kaushal Kant Verma is a Director at Weehum Pharmaceutical Private Limited (since 2022). The company operates in Pharma. Weehum Pharmaceutical Private Limited reported revenue of ₹46,180 (FY 2025).

DIN 09608717
Primary Designation Director
Industry Pharma
First Appointment 13 May 2022
Oldest Company Age 6 yrs
Largest company Weehum Pharmaceutical Private Limited · ₹46,180 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director13 May 20222020₹46,180 (FY 2025)Active

Board colleagues of Kaushal Kant Verma

Directorship timeline

Open interactive timeline →
Weehum Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Kaushal Kant Verma

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kaushal Kant Verma

Kaushal Kant Verma currently holds 1 directorship: Weehum Pharmaceutical Private Limited (Director, since 13 May 2022, revenue ₹46,180 (FY 2025)).

Kaushal Kant Verma was first appointed on 13 May 2022 as Director at Weehum Pharmaceutical Private Limited.

The current boards of Kaushal Kant Verma's companies include Pinki Kumari (Weehum Pharmaceutical Private Limited), Ravi Kant Yadav (Weehum Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available